Wearable ECG P-Wave/R-Wave Ratios for Amyloidosis Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing wearable devices for cardiac amyloidosis detection face challenges in accurately measuring R-wave amplitudes due to variability and interference, making it difficult to reliably detect early stages of the disease without requiring a 12-lead EKG or echocardiogram.
Innovation Solution
A wearable device that measures relative values or ratios of P-wave and R-wave features, such as amplitude, area, duration, and interval, over time, using a microprocessor and deep learning algorithms to filter out noise and correct distortions, allowing for early detection and surveillance of cardiac amyloidosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a 12-lead EKG is used to measure absolute R-wave amplitude for cardiac amyloidosis detection, then measurement precision is improved, but device complexity and ease of operation worsen
Solution Approach 1:
The patent extracts the essential diagnostic information (R-wave to P-wave amplitude ratio) from the complex 12-lead EKG system and implements it in a simplified two-lead wearable device. By focusing only on the necessary waveform parameters and their ratios rather than absolute values, the invention achieves cardiac amyloidosis detection capability with minimal leads, resolving the contradiction between measurement precision and device complexity.
Solution Approach 2:
The patent changes the measurement parameter from absolute R-wave amplitude to the ratio of R-wave amplitude to P-wave amplitude. This parameter transformation eliminates the need for precise absolute amplitude measurement while maintaining diagnostic accuracy for detecting progressive R-wave decline characteristic of cardiac amyloidosis, thereby enabling simple two-lead device implementation.
2Ease of operation
If absolute R-wave amplitude is measured with a two-electrode wearable device, then ease of operation is improved, but measurement precision and reliability worsen due to noise and impedance variability
Solution Approach 1:
The patent introduces the P-wave amplitude as an intermediary reference that mediates between the noisy absolute R-wave measurement and the diagnostic requirement. By expressing R-wave amplitude as a ratio relative to P-wave amplitude, the invention compensates for common-mode noise and impedance variations, maintaining measurement precision while enabling simple two-electrode wearable device operation.
3Loss of time
If early detection of cardiac amyloidosis is achieved through monitoring, then loss of time for intervention is reduced, but device complexity and measurement requirements increase
Solution Approach 1:
The patent implements preliminary monitoring action by enabling patients to self-administer ECG measurements at home using simple wearable devices. The system continuously or periodically captures ECG data and automatically analyzes R-wave to P-wave amplitude ratios, detecting early signs of cardiac amyloidosis progression before significant symptoms develop, thereby reducing intervention time without requiring complex hospital-based equipment.
Data Source
AI summary
An improved wearable device for detecting progression of Cardiac Amyloidosis based on changes in relative values of characteristics of P-wave and R-wave is disclosed. In an embodiment of the invention, two electrodes the device are connected to user's skin surface to obtain traces of ECG signals. Thereafter, correction factors are determined for the obtained traces of ECG signals. A microprocessor included in the device applies correction factors on the traces of ECG signals to obtain characteristics of P-wave and R-wave. Finally, the microprocessor determines the ratio of the characteristics (such as amplitude) of the P-wave to the characteristics (such as amplitude) of the R-wave and records said ratio. Still further, the microprocessor compares all such recorded ratios or features, to determine and display if there is disease progression.